Page 41 - GALENIKA MEDICAL JOURNAL

Literatura 23. Giustina A, Chanson P, Kleinberg D, Bronstein MD, Clemmons DR,
Klibanski A, et al. Acromegaly Consensus Group. Expert consensus
document: A consensus on the medical treatment of acromegaly.Nat
1. Gadelha MR, Kasuki L, Lim DST, Fleseriu M. Systemic Complications of Rev Endocrinol. 2014; 10:243-8.
Acromegaly and the Impact of the Current Treatment Landscape: An 24. Katznelson L, Laws ER Jr, Melmed S, Molitch ME, Murad MH, Utz A, et
Update. Endocr Rev. 2019; 1;40:268-332. al. Endocrine Society. Acromegaly: an endocrine society clinical practice
2. Melmed S. Medical progress: Acromegaly.N Engl J Med. 2006; guideline. J Clin Endocrinol Metab. 2014 Nov;99(11):3933-51.
14;355:2558-73. 25. Melmed S, Bronstein MD, Chanson P, Klibanski A, Casanueva FF,
3. Bollerslev J, Heck A, Olarescu NC. Management of endocrine disease. Wass JAH, et al. A Consensus Statement on acromegaly therapeutic
Individualized Management of Acromegaly.Eur J Endocrinol. 2019; outcomes. Nat Rev Endocrinol. 2018 Sep;14(9):552-61.
Aug;181(2):R57-R71. 26. Chanson P, Vialon M, Caron P. An update on clinical care for pregnant
4. Esposito D, Ragnarsson O, Granfeldt D, Marlow T, Johannsson G, Olsson women with acromegaly. Expert Rev Endocrinol Metab. 2019;14:85-96.
DS. Decreasing mortality and changes in treatment patterns in patients 27. Shen M, Tang Y, Shou X, Wang M, Zhang Q, Qiao N, et al. Surgical
with acromegaly from a nationwide study. Eur J Endocrinol 2018; 178 Results and Predictors of Initial and Delayed Remission for Growth
459-69. Hormone-Secreting Pituitary Adenomas Using the 2010 Consensus
5. Hoskuldsdottir GT, Fjalldal SB, Sigurjonsdottir HA. The incidence and Criteria in 162 Patients from a Single Center. World Neurosurg. 2018
prevalence of acromegaly, a nationwide study from 1955 through 2013. Nov 27:S1878-8750(18)32738-4.
Pituitary. 2015 Dec;18(6):803-7. 28. Buchfelder M, Schlaffer SM. The surgical treatment of acromegaly.
6. Ghazi AA, Amirbaigloo A, Dezfooli AA, Saadat N, Ghazi S, Pourafkari M, Pituitary; 2017 20 76-83.
et al. Ectopic acromegaly due to growth hormone releasing hormone. 29. Antunes X, Ventura N, Camilo GB, Wildemberg LE, Guasti A, Pereira PJM,
Endocrine. 2013; 43:293-302. et al. Predictors of surgical outcome and early criteria of remission in
7. Colao A, Grasso LFS, Giustina A, Melmed S, Chanson P, Pereira AM, et al. acromegaly. Endocrine.2018; 60:415-22.
Acromegaly. Nat Rev Dis Primers. 2019; 5:20. 30. Doknic M, Stojanovic M. The place of medical treatment of acromegaly
8. Bolfi F, Neves AF, Boguszewski CL, Nunes-Nogueira VS. Mortality in in Serbia: current status. Vojnosanitetski pregled 2020.
acromegaly decreased in the last decade: a systematic review and 31. Neggers SJ, Pronin V, Balcere I, Lee MK, Rozhinskaya L, Bronstein MD, et
meta-analysis. Eur J Endocrinol.2018; 179:59-71. al. Lanreotide autogel 120 mg at extended dosing intervals in patients
9. Dal J, Feldt-Rasmussen U, Andersen M, Kristensen LØ, Laurberg P, with acromegaly biochemically controlled with octreotide LAR: the LEAD
Pedersen L, et al. Acromegaly incidence, prevalence, complications and study. Eur J Endocrinol. 2015; 173:313-23.
long-term prognosis: a nationwide cohort study. Eur J Endocrinol. 2016; 32. Chin SO, Ku CR, Kim BJ, Kim SW, Park KH, Song KH, et al. Medical
175:181-90. Treatment with Somatostatin Analogues in Acromegaly:
10. Schilbach K, Gar C, Lechner A, Nicolay SS, Schwerdt L, Haenelt M, Dal J, PositionStatement. Endocrinol Metab (Seoul).2019;34:53-62.
et al. Determinants of the growth hormone nadir during oral glucose 33. Colao A, Auriemma RS, Lombardi G, Pivonello R. Resistance to
tolerance test in adults. Eur J Endocrinol. 2019. somatostatin analogs in acromegaly. Endocr Rev.2011;32:247-71.
11. Pivonello R, Auriemma RS, Grasso LF, Pivonello C, Simeoli C, Patalano 34. Gadelha MR, Bronstein MD, Brue T, Coculescu M, Fleseriu M, Guitelman
R, et al. Complications of acromegaly: cardiovascular, respiratory and M, et al. Pasireotide C2402 Study Group. Pasireotide versus continued
metabolic comorbidities.Pituitary. 2017; 20:46-62. treatment with octreotide or lanreotide in patients with inadequately
12. Giustina A, Barkan A, Beckers A, Biermasz N, Biller BMK, Boguszewski controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet
C, et al. A Consensus on the Diagnosis and Treatment of Acromegaly Diabetes Endocrinol.2014; 2:875-84.
Comorbidities: An Update. J Clin Endocrinol Metab. 2020 Apr 35. Coopmans EC, Muhammad A, van der Lely AJ, Janssen JAMJL, Neggers
1;105(4):dgz096. SJCMM. How to Position Pasireotide LAR Treatment in Acromegaly. Clin
13. Sharma MD, Nguyen AV, Brown S, Robbins RJ. Cardiovascular Disease in Endocrinol Metab.2019; 104:1978-88.
Acromegaly. Methodist Debakey Cardiovasc J. 2017; 13:64-7. 36. Giustina A, Biermasz N, Casanueva FF, Fleseriu M, Mortini P, Strasburger
14. Sherin RPV, Vietor NO, Usman A, Hoang TD, Shakir MKM. Cardiovascular C, et al. Consensus on criteria for acromegaly diagnosis and remission.
Disorders Associated WithAcromegaly: an Update. Endocr Pract. 2024 Pituitary. 2024 Feb;27(1):7-22.
15. Wolters TLC, Netea MG, Riksen NP, Hermus ARMM, Netea-Maier RT. 37. Van der Lely AJ, Biller BMK, Brue T, Buchfelder M, Ghigo E, Gomez R,
Acromegaly, inflammation and cardiovascular disease: a review. Rev et al. Long-Term Safety of Pegvisomant in Patients with Acromegaly:
Endocr Metab Disord. 2020. Comprehensive Review of 1288 Subjects in ACROSTUDY. J Clin Endo
Metab 2012; 97: 1589-97
16. Hannon AM, Thompson CJ, Sherlock M. Diabetes in Patients With
Acromegaly. Curr Diab Rep. 2017 Feb;17(2):8. 38. Neggers SJ, Lely AJV. Pegvisomant for acromegaly: does it always
works? Arch Endocrinol Metab. 2019; 63:318-9.
17. Muhammad A, van der Lely AJ, Delhanty PJD, Dallenga AHG, Haitsma
IK, Janssen JAMJL, et al. Efficacy and Safety of Switching to Pasireotide 39. Buchfelder M, Van der Lely AJ, Biller BMK, Webb SM, Brue T, Strasburger
in Patients With Acromegaly Controlled With Pegvisomant and First- CJ, Ghigo E, et al. Long-term treatment with pegvisomant: observations
Generation Somatostatin Analogues (PAPE Study). J Clin Endocrinol from 2090 acromegaly patients in ACROSTUDY.Eur J Endocrinol. 2018;
Metab. 2018 Feb 1;103(2):586-95. 179:419-27.
18. García-Álvarez M, Climent V. Sleep apnea and cardiovascular 40. Daly AF, Cano DA, Venegas-Moreno E, Petrossians P, Dios E, Castermans
complications of the acromegaly. Response to the medical treatment. E, et al. AIP and MEN1 mutations and AIP immunohistochemistry in
Minerva Endocrinol. 2019;44:159-68. pituitary adenomas in a tertiary referral center. Endocr Connect. 2019
Apr;8(4):338-48.
19. Mazziotti G, Lania AGA, Canalis E. Management of endocrine disease:
Bone disorders associated with acromegaly: mechanisms and 41. Doknic M, Stojanovic M, Miljic D, Milicevic M. Medical treatment of
treatment. Eur J Endocrinol. 2019;181: R45-R56. acromegaly - When the tumor size matters: A narrative review. Growth
Horm IGF Res. 2024 Oct;78:101608
20. Bima C, Chiloiro S, Mormando M, Piacentini S, Bracaccia E, Giampietro
A, et al. Understanding the effect of acromegaly on the human 42. Higham CE, Atkinson AB, Aylwin S, Bidlingmaier M, Drake WM, Lewis A,
skeleton.. Expert Rev Endocrinol Metab. 2016. et al. Effective combination treatment with cabergoline and low-dose
pegvisomant in active acromegaly: a prospective clinical trial. 2012; J
21. Pelsma ICM, Kroon HM, van Trigt VR, Pereira AM, Kloppenburg M, Clin Endocrinol Metab 97:1187-93
Biermasz NR, et al. Clinical and radiographic assessment of peripheral
joints in controlled acromegaly. Pituitary. 2022. 43. Neggers SJ, Franck SE, de Rooij FW, Dallenga AH, Poublon RM, Feelders
RA, et al. Long-term efficacy and safety of pegvisomant in combination
22. Chiloiro S, Giampietro A, Gagliardi I, Bondanelli M, Epifani V, Milardi with long-acting somatostatin analogs in acromegaly. J Clin Endocrinol
D,et al. Systemic comorbidities of acromegaly in real-life experience: Metab. 2014 Oct;99(10):3644-52.
which difference among young and elderly patients? Endocrine. 2023
Apr;80(1):142-51. 44. Fleseriu M, Hoffman AR, Katznelson L; AACE Neuroendocrine and
Pituitary Scientific Committee. American assosiation of clinical
endocrinologists and american colledge of endocrinology disease state
clinical rewiev: management of acromegaly patients: what is the role of
preoperative medical therapy? Endocr Pract. 2015; 21:668-73.

REVIJALNI RADOVI Galenika Medical Journal, 2024; 3(12):30-40. 39